Dissecting Emerging Data in Metastatic Breast Cancer

Mabel Mardones, MD, discusses implications of data for Dato-DXd and sacituzumab govitecan in frontline metastatic triple-negative breast cancer.

Mabel Mardones, MD, discusses how Dato-DXd and sacituzumab govitecan may affect first-line treatment for metastatic triple-negative breast cancer.

Maxwell Lloyd, MD, discusses phase 3 data from DESTINY-Breast11 and DESTINY-Breast05 evaluating T-DXd in neoadjuvant and adjuvant HER2-positive breast cancer.

Maxwell Lloyd, MD, details the implications of DESTINY-Breast11 and DESTINY-Breast05 data for the use of T-DXd in early-stage HER2-positive breast cancer.

Heather McArthur, MD, MPH, discusses the expanding clinical impact of ADCs in HER2-positive breast cancer.

Hope S. Rugo, MD, FASCO, discusses key considerations and unanswered questions arising from the DESTINY-Breast09 trial in HER2-positive breast cancer.

Kevin Kalinsky, MD, MS, FASCO, discusses potential new roles for the CLEOPATRA and DESTINY-Breast09 regimens in the HER2-positive breast cancer paradigm.

Sara M. Tolaney, MD, MPH, discusses data showing that T-DXd plus pertuzumab improved PFS vs SOC THP in first-line HER2-positive breast cancer.

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, details the clinical implications for first-line T-DXd/pertuzumab for the treatment of patients with HER2-positive breast cancer.